Compare Stocks → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BCLINASDAQ:CSBRNASDAQ:FENCNASDAQ:IDRANASDAQ:NTGN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$0.55+3.8%$0.47$0.13▼$3.34$35.88M0.281.05 million shs201,562 shsCSBRChampions Oncology$5.08+0.2%$10.15$7.19▼$14.68$68.92M0.392,239 shs1,377 shsFENCFennec Pharmaceuticals$9.07-1.8%$10.05$6.30▼$11.92$250.40M0.38130,251 shs182,107 shsIDRAIdera Pharmaceuticals$0.50$0.22▼$8.67$450.52M1.25464,030 shs21,870 shsNTGNNeon Therapeutics$3.07$3.03$0.88▼$6.25$88.93M-0.81516,108 shsN/AElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics+3.81%+0.78%-16.79%+75.69%-80.40%CSBRChampions Oncology-3.42%+0.99%-2.31%-16.72%+1.60%FENCFennec Pharmaceuticals-1.84%-6.49%-17.55%-12.96%+14.09%IDRAIdera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%NTGNNeon Therapeutics0.00%0.00%0.00%0.00%0.00%Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot NowMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCLIBrainstorm Cell Therapeutics0.7271 of 5 stars0.03.00.04.71.90.00.6CSBRChampions Oncology3.7533 of 5 stars3.34.00.04.60.62.50.0FENCFennec Pharmaceuticals2.4636 of 5 stars3.50.00.00.02.42.51.9IDRAIdera PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANTGNNeon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCLIBrainstorm Cell Therapeutics2.00HoldN/AN/ACSBRChampions Oncology2.50Moderate Buy$7.5047.64% UpsideFENCFennec Pharmaceuticals3.00Buy$17.3391.11% UpsideIDRAIdera PharmaceuticalsN/AN/AN/AN/ANTGNNeon TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest FENC, BCLI, NTGN, CSBR, and IDRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2024FENCFennec PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$16.003/13/2024CSBRChampions OncologyCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($0.08) per shareN/ACSBRChampions Oncology$53.87M1.28N/AN/A$0.34 per share14.94FENCFennec Pharmaceuticals$21.25M11.57N/AN/A($0.43) per share-21.09IDRAIdera PharmaceuticalsN/AN/AN/A0.29$0.56 per shareN/ANTGNNeon TherapeuticsN/AN/AN/AN/A$0.50 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCLIBrainstorm Cell Therapeutics-$17.19M-$0.41N/AN/AN/AN/AN/A-376.40%5/20/2024 (Estimated)CSBRChampions Oncology-$5.34M-$0.72N/A∞N/A-19.76%-850.72%-32.62%7/22/2024 (Estimated)FENCFennec Pharmaceuticals-$16.05M-$0.61N/A12.96N/A-75.50%N/A-73.64%5/9/2024 (Estimated)IDRAIdera Pharmaceuticals$98.09M-$0.32N/AN/AN/AN/A-68.74%-34.26%N/ANTGNNeon Therapeutics-$79.78M-$2.86N/AN/AN/AN/A-199.09%-137.14%N/ALatest FENC, BCLI, NTGN, CSBR, and IDRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023FENCFennec Pharmaceuticals$0.02-$0.10-$0.12-$0.10$9.47 million$9.74 million3/12/2024Q3 2024CSBRChampions OncologyN/A-$0.19-$0.19-$0.19N/A$12.02 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/ACSBRChampions OncologyN/AN/AN/AN/AN/AFENCFennec PharmaceuticalsN/AN/AN/AN/AN/AIDRAIdera PharmaceuticalsN/AN/AN/AN/AN/ANTGNNeon TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCLIBrainstorm Cell TherapeuticsN/A0.240.24CSBRChampions OncologyN/A0.600.60FENCFennec PharmaceuticalsN/A3.563.27IDRAIdera PharmaceuticalsN/A1.561.56NTGNNeon Therapeutics0.431.583.00OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCLIBrainstorm Cell Therapeutics14.33%CSBRChampions Oncology41.30%FENCFennec Pharmaceuticals55.51%IDRAIdera Pharmaceuticals12.18%NTGNNeon Therapeutics54.71%Insider OwnershipCompanyInsider OwnershipBCLIBrainstorm Cell Therapeutics5.45%CSBRChampions Oncology45.69%FENCFennec Pharmaceuticals11.25%IDRAIdera Pharmaceuticals5.05%NTGNNeon Therapeutics38.93%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBCLIBrainstorm Cell Therapeutics2968.34 million64.62 millionOptionableCSBRChampions Oncology14313.59 million7.38 millionOptionableFENCFennec PharmaceuticalsN/A27.10 million24.05 millionOptionableIDRAIdera Pharmaceuticals3262.36 million59.21 millionOptionableNTGNNeon Therapeutics10228.97 millionN/ANot OptionableFENC, BCLI, NTGN, CSBR, and IDRA HeadlinesSourceHeadlineNeon Trap Defensekotaku.com - April 14 at 12:18 AMBCYC Bicycle Therapeutics plcseekingalpha.com - April 9 at 1:09 PMneon oscillatorhackaday.com - March 20 at 10:44 AMNTGN_old Historical Datainvesting.com - February 20 at 3:42 PM2000 Plymouth Neoncars.com - January 13 at 7:49 PMNBCO Neon Bloom, Inc.seekingalpha.com - December 22 at 4:41 AMKansas City Ferris wheel could be out-dazzled by what will soon lie below: Neon Alleykansascity.com - November 13 at 11:05 PMStarfield Neon shops and locations – every vendor in Neonvideogamer.com - November 4 at 2:31 PMA Nixie Clock With Neon Bulb Logichackaday.com - October 5 at 7:57 AMStarfield | Where To Get Neon (Ne)hardcoregamer.com - September 29 at 8:17 AMStarfield Neon City guide – everything you need to knowvideogamer.com - September 14 at 8:09 AMStarfield: All Shops in Neon Citytwinfinite.net - September 10 at 4:42 PMShadows in Neonign.com - September 9 at 12:52 AMStarfield Neon city guidepcgamesn.com - August 19 at 11:48 PMApex Legends Neon Network Collection Eventign.com - August 4 at 10:49 PMFab Five: Neon fashion finds to brighten up your summer wardrobevancouversun.com - August 1 at 12:37 AMNeon White physical edition for PS5, Switch launches September 15gematsu.com - July 21 at 10:14 AMFast-paced platformer 'Neon White' is coming to Xboxengadget.com - June 22 at 9:32 AMAriana Madix Stuns in Neon Pantsuit Before Bombshell Scandoval Interviewaol.com - June 10 at 8:17 AMneon signhackaday.com - May 21 at 5:30 PMJessica Simpson Has Strong AF Abs And Toned Legs In A Neon SKIMS Bikini In An IG Photowomenshealthmag.com - May 7 at 10:17 AMEverything New In Fortnite Chapter 4 Season 2: Neon Lights, Katana Fights, And Moregamespot.com - April 12 at 6:19 PMMacbeth review – neon-tinted remix plays like a cinematic thrillertheguardian.com - March 1 at 10:35 PMLea Michele Rocks Neon One-Piece Swimsuit To Do Yoga While Paddleboarding: Photoshollywoodlife.com - March 1 at 10:35 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBrainstorm Cell TherapeuticsNASDAQ:BCLIBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Champions OncologyNASDAQ:CSBRChampions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.Fennec PharmaceuticalsNASDAQ:FENCFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Idera PharmaceuticalsNASDAQ:IDRAAceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.Neon TherapeuticsNASDAQ:NTGNNeon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.